Medicare IVIG Access Enhancement Act of 2023

This bill expands Medicare coverage for in-home administration of intravenous immune globulin (IVIG) to include treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), effective January 1, 2026. It amends Medicare law to add these conditions to the list of covered primary immune deficiency diseases, directly affecting Medicare beneficiaries with CIDP or MMN who currently lack coverage for in-home IVIG. The bill also allows Medicare payment adjustments based on whether IVIG is used for primary immune deficiency or these new neurological conditions, as determined by the Secretary through formal rulemaking. This creates a specific policy change to broaden access for two neurological conditions previously excluded from in-home IVIG coverage.